OBJECTIVES: Individualized treatment for bipolar disorder based on neuroimaging treatment targets remains elusive. To address this shortcoming, we developed a linguistic machine learning system based on a cascading genetic fuzzy tree (GFT) design called the LITHium Intelligent Agent (LITHIA). Using multiple objectively defined functional magnetic resonance imaging (fMRI) and proton magnetic resonance spectroscopy (1 H-MRS) inputs, we tested whether LITHIA could accurately predict the lithium response in participants with first-episode bipolar mania. METHODS: We identified 20 subjects with first-episode bipolar mania who received an adequate trial of lithium over 8 weeks and both fMRI and 1 H-MRS scans at baseline pre-treatment. We trained LITHIA using 18 1 H-MRS and 90 fMRI inputs over four training runs to classify treatment response and predict symptom reductions. Each training run contained a randomly selected 80% of the total sample and was followed by a 20% validation run. Over a different randomly selected distribution of the sample, we then compared LITHIA to eight common classification methods. RESULTS: LITHIA demonstrated nearly perfect classification accuracy and was able to predict post-treatment symptom reductions at 8 weeks with at least 88% accuracy in training and 80% accuracy in validation. Moreover, LITHIA exceeded the predictive capacity of the eight comparator methods and showed little tendency towards overfitting. CONCLUSIONS: The results provided proof-of-concept that a novel GFT is capable of providing control to a multidimensional bioinformatics problem-namely, prediction of the lithium response-in a pilot data set. Future work on this, and similar machine learning systems, could help assign psychiatric treatments more efficiently, thereby optimizing outcomes and limiting unnecessary treatment.
OBJECTIVES: Individualized treatment for bipolar disorder based on neuroimaging treatment targets remains elusive. To address this shortcoming, we developed a linguistic machine learning system based on a cascading genetic fuzzy tree (GFT) design called the LITHium Intelligent Agent (LITHIA). Using multiple objectively defined functional magnetic resonance imaging (fMRI) and proton magnetic resonance spectroscopy (1 H-MRS) inputs, we tested whether LITHIA could accurately predict the lithium response in participants with first-episode bipolar mania. METHODS: We identified 20 subjects with first-episode bipolar mania who received an adequate trial of lithium over 8 weeks and both fMRI and 1 H-MRS scans at baseline pre-treatment. We trained LITHIA using 18 1 H-MRS and 90 fMRI inputs over four training runs to classify treatment response and predict symptom reductions. Each training run contained a randomly selected 80% of the total sample and was followed by a 20% validation run. Over a different randomly selected distribution of the sample, we then compared LITHIA to eight common classification methods. RESULTS:LITHIA demonstrated nearly perfect classification accuracy and was able to predict post-treatment symptom reductions at 8 weeks with at least 88% accuracy in training and 80% accuracy in validation. Moreover, LITHIA exceeded the predictive capacity of the eight comparator methods and showed little tendency towards overfitting. CONCLUSIONS: The results provided proof-of-concept that a novel GFT is capable of providing control to a multidimensional bioinformatics problem-namely, prediction of the lithium response-in a pilot data set. Future work on this, and similar machine learning systems, could help assign psychiatric treatments more efficiently, thereby optimizing outcomes and limiting unnecessary treatment.
Authors: Stephen M Strakowski; David E Fleck; Jeffrey Welge; James C Eliassen; Matthew Norris; Michelle Durling; Richard A Komoroski; Wen-Jang Chu; Wade Weber; Jonathan A Dudley; Thomas J Blom; Amanda Stover; Christina Klein; Jeffrey R Strawn; Melissa P DelBello; Jing-Huei Lee; Caleb M Adler Journal: Bipolar Disord Date: 2016-09-19 Impact factor: 6.744
Authors: Ahmad Khodayari-Rostamabad; James P Reilly; Gary M Hasey; Hubert de Bruin; Duncan J Maccrimmon Journal: Clin Neurophysiol Date: 2013-05-15 Impact factor: 3.708
Authors: Janaina Mourão-Miranda; Leticia Oliveira; Cecile D Ladouceur; Andre Marquand; Michael Brammer; Boris Birmaher; David Axelson; Mary L Phillips Journal: PLoS One Date: 2012-02-15 Impact factor: 3.240
Authors: Mauricio H Serpa; Yangming Ou; Maristela S Schaufelberger; Jimit Doshi; Luiz K Ferreira; Rodrigo Machado-Vieira; Paulo R Menezes; Marcia Scazufca; Christos Davatzikos; Geraldo F Busatto; Marcus V Zanetti Journal: Biomed Res Int Date: 2014-01-19 Impact factor: 3.411
Authors: Wenjing Zhang; Yuan Xiao; Huaiqiang Sun; L Rodrigo Patino; Maxwell J Tallman; Wade A Weber; Caleb M Adler; Christina Klein; Jeffrey R Strawn; Fabiano G Nery; Qiyong Gong; John A Sweeney; Su Lui; Melissa P DelBello Journal: Neuropsychopharmacology Date: 2018-06-18 Impact factor: 7.853
Authors: Du Lei; Wenbin Li; Kun Qin; Yuan Ai; Maxwell J Tallman; L Rodrigo Patino; Jeffrey A Welge; Thomas J Blom; Christina C Klein; David E Fleck; Qiyong Gong; Caleb M Adler; Jeffrey R Strawn; John A Sweeney; Melissa P DelBello Journal: Neuropsychopharmacology Date: 2022-10-13 Impact factor: 8.294
Authors: Sarah A Thomas; Rachel E Christensen; Elana Schettini; Jared M Saletin; Amanda L Ruggieri; Heather A MacPherson; Kerri L Kim; Daniel P Dickstein Journal: J Affect Disord Date: 2018-12-24 Impact factor: 4.839